Inovelon (Rufinamide)

• Rufinamide is an antiepileptic used primarily in the management of refractory seizure disorders.
• Lennox‑Gastaut syndrome: reduces the frequency of drop attacks and other seizure types associated with this severe childhood epilepsy.
• Adjunctive therapy in Lennox‑Gastaut syndrome: employed alongside other antiepileptics to improve overall seizure control.
• Patients with refractory seizures: may be considered for those who have not responded adequately to conventional medications.

• Rufinamide modulates neuronal voltage‑gated sodium channels, preferentially stabilizing the inactivated state and thereby reducing the rapid firing of neurons. This attenuation of sodium influx diminishes neuronal hyperexcitability, which contributes to the generation and propagation of epileptic discharges. The precise molecular interactions remain incompletely defined, but the overall effect is a decrease in seizure activity. By limiting repetitive neuronal firing, the drug helps to maintain more stable cortical activity.

Rufinamide may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: transient sensation of light‑headedness or imbalance.
• Somnolence: increased sleepiness, especially after dose initiation.
• Nausea or vomiting: gastrointestinal discomfort that may lessen with continued use.
• Headache: mild to moderate pain often reported early in therapy.

Serious or Rare Side Effects

• Severe rash or Stevens‑Johnson syndrome: requires immediate medical attention.
• Hepatic dysfunction: elevated liver enzymes or jaundice should be monitored.
• Suicidal ideation or severe depression: any mood changes must be reported promptly.

• When prescribing Rufinamide, clinicians should consider several safety measures.
• Pregnancy: Category C; weigh potential benefits against risks before use.
• Renal impairment: dose may require adjustment; monitor renal function regularly.
• Hepatic impairment: use with caution; periodic liver‑function tests are advised.
• Concomitant use with enzyme inducers: may reduce plasma levels, potentially diminishing efficacy.
• Avoid abrupt discontinuation: sudden cessation can precipitate seizure worsening.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Rufinamide interacts with several medicines; awareness of the interaction level guides management.

Major Interactions (Avoid)

• Strong enzyme inducers (e.g., carbamazepine, phenytoin, phenobarbital): markedly lower Rufinamide concentrations, reducing therapeutic effect.
• Combined use with other sodium‑channel blockers at high doses: may increase risk of central nervous system depression.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: Rufinamide can reduce hormonal efficacy; consider alternative contraception.
• Valproate: may increase Rufinamide plasma levels, requiring closer monitoring.
• Alcohol: additive CNS depressant effects may enhance dizziness or somnolence.